Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.

Ozberk, D; Haywood, A; Sutherland, HG; Yu, C; Albury, CL; Zunk, M; George, R; Good, P; Griffiths, LR; Hardy, J; Haupt, LM

Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.

Ozberk, D Haywood, A Sutherland, HG Yu, C Albury, CL Zunk, M George, R Good, P

Griffiths, LR Hardy, J Haupt, LM

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Sci Rep, 2022, 12, (1), pp. 17422
Issue Date:: 2022-10-19

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (965.78 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Ozberk, D
dc.contributor.author	Haywood, A
dc.contributor.author	Sutherland, HG
dc.contributor.author	Yu, C
dc.contributor.author	Albury, CL
dc.contributor.author	Zunk, M
dc.contributor.author	George, R
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.contributor.author	Griffiths, LR
dc.contributor.author	Hardy, J
dc.contributor.author	Haupt, LM
dc.date.accessioned	2023-05-30T02:07:39Z
dc.date.available	2022-09-23
dc.date.available	2023-05-30T02:07:39Z
dc.date.issued	2022-10-19
dc.identifier.citation	Sci Rep, 2022, 12, (1), pp. 17422
dc.identifier.issn	2045-2322
dc.identifier.issn	2045-2322
dc.identifier.uri	http://hdl.handle.net/10453/170542
dc.description.abstract	Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investigating genetic factors that contribute to pain and analgesia response. This is the first association study on polymorphisms in KCNJ6 and response to methadone for pain management in advanced cancer. Fifty-four adult patients with advanced cancer were recruited across two study sites in a prospective, open label, dose individualisation study. Significant associations have been previously shown for rs2070995 and opioid response in opioid substitution therapy for heroin addiction and studies in chronic pain, with mixed results seen in postoperative pain. In this study, no associations were shown for rs2070995 and methadone dose or pain score, consistent with other studies conducted in patients receiving opioids for pain in advanced cancer. There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	Sci Rep
dc.relation.isbasedon	10.1038/s41598-022-21180-w
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.mesh	Adult
dc.subject.mesh	Humans
dc.subject.mesh	Methadone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Pain Management
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Chronic Pain
dc.subject.mesh	Neoplasms
dc.subject.mesh	Death
dc.subject.mesh	G Protein-Coupled Inwardly-Rectifying Potassium Channels
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Death
dc.subject.mesh	Methadone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Adult
dc.subject.mesh	G Protein-Coupled Inwardly-Rectifying Potassium Channels
dc.subject.mesh	Pain Management
dc.subject.mesh	Chronic Pain
dc.subject.mesh	Adult
dc.subject.mesh	Humans
dc.subject.mesh	Methadone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Pain Management
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Chronic Pain
dc.subject.mesh	Neoplasms
dc.subject.mesh	Death
dc.subject.mesh	G Protein-Coupled Inwardly-Rectifying Potassium Channels
dc.title	Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
dc.type	Journal Article
utslib.citation.volume	12
utslib.location.activity	England
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
dc.date.updated	2023-05-30T02:07:36Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	12
utslib.citation.issue	1

Abstract:

Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investigating genetic factors that contribute to pain and analgesia response. This is the first association study on polymorphisms in KCNJ6 and response to methadone for pain management in advanced cancer. Fifty-four adult patients with advanced cancer were recruited across two study sites in a prospective, open label, dose individualisation study. Significant associations have been previously shown for rs2070995 and opioid response in opioid substitution therapy for heroin addiction and studies in chronic pain, with mixed results seen in postoperative pain. In this study, no associations were shown for rs2070995 and methadone dose or pain score, consistent with other studies conducted in patients receiving opioids for pain in advanced cancer. There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/170542